Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
#SEC-Update $RNAZ: $0.21
Sector: Healthcare
YTD: -98%
1 Yr: -97%
SEC reported Today (07DEC2023) that Lind Global Fund II LP has NEWLY-BOUGHT 2,500,000 $RNAZ shares.
Approx Trxn Value :600.00K
Own %: 9.90%
TransCode Therapeutics Raises $9.7 Million to Catapult Cancer Treatment into the RNA Revolution
PUBLISHED / MODIFIED DEC 04 2023
CSIMARKET TEAM / CSIMARKET.COM
TransCode Therapeutics Raises $9.7 Million in Capital to Accelerate Breakthroughs in RNA Oncology
TransCode Therapeutics, a leading RNA oncology company dedicated to transforming cancer treatment through innovative RNA therapeutics, recently announced the closing of two successful funding rounds. The company successfully completed a registered direct offering, generating $1.2 million, and followed up with a public offering, generating an impressive $8.5 million in gross proceeds. These capital infusions will enable TransCode Therapeutics to drive advancements in RNA-based cancer treatments, offering new hope to patients worldwide.
In its registered direct offering, TransCode Therapeutics sold 5,000,000 shares of common stock at an attractive price of $0.242 per share. By strategically utilizing the at-the-market pricing option provided by Nasdaq rules, the company ensured efficient and expedited access to capital to fuel its ambitious mission. This offering signifies the support and confidence of investors in TransCode Therapeutics' potential to revolutionize cancer treatment using RNA therapeutics.
Building on the success of its registered direct offering, TransCode Therapeutics initiated a public offering with tremendous results. The offering consisted of 16,863,000 shares of common stock or pre-funded warrants, which were entirely sold. Priced at $0.51 per share, which includes the pre-funded warrant exercise price of $0.01 per share, this public offering raised a substantial $8.5 million in gross proceeds. This demonstrates the strong interest and recognition from institutional and retail investors in TransCode Therapeutics' groundbreaking work.
To further underscore investor interest and confidence in TransCode Therapeutics, the underwriters were granted a 45-day option to purchase up to 2,339,200 additional shares of common stock or pre-funded warrants at the public offering price. Notably, this option has been partially exercised, with the underwriters acquiring 1,163,000 pre-funded warrants at the closing. This further validates the growing excitement surrounding the potential of RNA-based therapies and TransCode Therapeutics' well-positioned market stance.
TransCode Therapeutics aims to leverage this newly raised capital to drive advancements in RNA therapeutics for cancer treatment. The company's groundbreaking approach utilizes RNA, a vital molecule in biology, to develop therapeutics that can selectively target and eliminate cancer cells with high precision. With the potential to revolutionize current cancer treatment protocols, TransCode Therapeutics is at the forefront of a promising frontier in medical science.
The raised funds will be allocated towards expanding TransCode Therapeutics' research and development programs, conducting further clinical trials, and advancing its pipeline of innovative RNA therapeutics. By accelerating the development and commercialization of its investigational therapies, the company aims to address critical unmet medical needs in cancer treatment, providing patients with more effective and less invasive options.
TransCode Therapeutics' successful funding rounds highlight the growing recognition of the immense potential of RNA-based therapeutics in revolutionizing cancer treatment. As the world grapples with the persistent challenges posed by cancer, companies like TransCode Therapeutics are at the forefront, spearheading cutting-edge research and innovation that offer new hope and improved outcomes for patients.
With its recent capital infusion totaling $9.7 million, TransCode Therapeutics is primed to continue making significant strides in the burgeoning field of RNA oncology. This financial support will enable the company to accelerate breakthroughs, drive clinical advancements, and move closer to realizing its vision of transforming cancer treatment through RNA therapeutics. In doing so, TransCode Therapeutics has positioned itself as a true pioneer in the fight against cancer.
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at this year’s San Antonio Breast Cancer Symposium scheduled to take place December 5-9 in San Antonio, TX.
The abstract, “Development of TTX-MC138, a First-In-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins” will be presented as a poster. The poster will describe the clinical development of TTX-MC138, a therapeutic miR-10b inhibitor, delivered to metastatic tumor cells that has elicited complete responses and life-long disease remissions in preclinical models of adenocarcinoma. The poster details the IND-enabling work in support of the Phase 0 trial with Cu64-labeled TTX-MC138 as well as initial results from the trial. The trial involves injection of a microdose of Cu64-labeled TTX-MC138 into stage IV breast cancer patients, followed by positron emission tomography-magnetic resonance imaging (PET-MRI). The trial seeks to determine the pharmacokinetics of TTX-MC138 and its uptake in metastatic lesions. Studies that will be presented in support of the Phase 0 trial include dosimetry/pharmacokinetic (PK) and tissue distribution, as well as metabolite analysis in non-human primates. In addition, initial clinical data on drug candidate PK and accumulation in clinical metastases, as well as drug candidate stability, will be discussed.
TransCode believes that the impact of this work is three-fold. First, TransCode believes these data show that TTX-MC138 has the potential to accumulate in human metastases as occurred in preclinical animal studies. TransCode believes this supports further clinical development of the therapeutic candidate because it shows that delivery of the therapeutic candidate to metastases is feasible. Second, the Phase 0 trial has the potential to reveal the pharmacokinetic behavior of TTX-MC138 which could inform dosing during therapy. Third, if TTX-MC138 reaches late-stage clinical trials, the radiolabeled therapeutic candidate could be used to select patients for treatment in the trial based on which patients’ metastases accumulate the drug candidate. TransCode believes that these results also have the potential to support further clinical trials using TTX-MC138 to treat metastatic cancer and, by addressing the issue of drug delivery, enable clinical development of a wide array of TTX-based therapeutic candidates.
About TransCode Therapeutics
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. Another of the company’s drug candidates, TTX-siPDL1, focuses on treating tumors by targeting a protein called Programmed death-ligand 1 (PD-L1). TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the preliminary data from a Phase 0 clinical trial with TransCode’s lead candidate, TTX-MC138, statements concerning expected clinical results of TransCode’s therapeutic candidates, statements concerning the results of RNA research, statements concerning the potential for treating cancer with RNA therapeutics, statements concerning the timing and outcome of expected regulatory filings and clinical trials, including the first-in-human study of TTX-MC138 currently underway and whether this study will demonstrate proof-of-mechanism, and statements concerning TransCode’s portfolio of drug candidates and TTX technology platform generally. Of note, a Phase 0 clinical trial is an exploratory study, conducted under an exploratory Investigational New Drug application. Exploratory IND studies usually involve very limited human exposure to a therapeutic candidate to evaluate mechanism of action in order to inform potential clinical evaluation in future clinical studies, but otherwise have no therapeutic intent. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.
For more information, please contact:
TransCode Therapeutics, Inc.
Alan Freidman, VP Investor Relations
alan.freidman@transcodetherapeutics.com
Company Profile
TransCode Therapeutics, Inc.
Website: https://transcodetherapeutics.com
Press Release Actions
Print
Download PDF
Subscribe via RSS
Subscribe via ATOM
Javascript
Recommended Reading
December 04, 2023 16:10 ET
Source:
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
November 30, 2023 14:53 ET
Source:
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
$IMTL Review Control™ President Frank Casella attended the National Franchise Show in Tampa this past weekend. He said: "The show is a great opportunity to see old friends and clients, and connect with new Franchisors for potential future partnerships with the Company.
I disagree with you guys. I think Henry is a marketing genius! Do any of you really think he’s never thought about a pre-recorded message??? He is a businessman… In my opinion he did this on purpose to drive to share price down so he can buy back even more shares… At the end of the day that makes him more money. Henry is not in a hurry because he knows what is in front of him and doesn’t need the money at this very second. I truly believe he did this on purpose to drive the price down and get the flippers shares for himself. That’s my thoughts & ive been watching him for a long time.
Are you still 99% on the K being filed by 6/4?
Excited for Wednesday!
Does anyone know if dilution is almost over? Shares in issue are up to 10 billion from I think it was 5 a month or so ago correct? If CEO stops dilution this is going to run like crazy! IMO
Interesting... I made a ton of money here & still hold 80% of my shares....
Sell off coming Monday... I knew I should’ve sold some today... The price will be back in a few weeks & will have new 52 week high by May but Monday will be painful...
I sold millions at .0098 without a problem...
Those of you doing DD on board have done a great job! You have stated though that he can do a share buyback while not being current… Henry seems to think he cannot… it makes me nervous that he is either lying or doesn’t know… Both are concerning
How already if you haven’t sold a share? I am with you though and have been here since 2016... I think Henry’s going to make it rain!
Good call!!! You must not be very familiar with the OTC! Shocked anyone follows you
New 52 week high!!
Getting ready to break through that 52 week high!
The ask is thin! Big day coming...
I would say it depends on what he says. Henry won’t go silent and not post this week… He will at least give some sort of a PR or an update on what’s going on. IMO
That’s what I was hoping for but wasn’t sure (Was hoping somebody had more info on this). With some dilution going on & the price holding steady I figure we are ready to takeoff soon! Was thinking about loading more...
Does anybody know how much dilution was here last week? Seems like there was quite a bit...
Anyone know what PHIG is?
I understand. I was a little off topic just wondering why he told you that when everything I read has him just under 43 million shares... if it wasn’t you that stated he said that, my apologies.
You stated a while back that Henry is the largest shareholder. On record he only owns 43 million. I find it interesting that he cannot buy back shares right now not being current but he can do insider purchasing… He is not disclose buying more shares so therefore how would he be the largest shareholder?
Not current by the end of the month... Is this your opinion or from Henry?
Are you just mad because chart master called this run and you’ve been off with your predictions time after time. You must be getting embarrassed at this point
Great day to be in PHIL & NECA!!!
I didn’t have a problem... you just can’t buy more than 999,999 at a time
We are aware of the same financial information as him… Most just don’t believe that it’s real...
My hope is this is part of his plan... Go dark to keep price from going up. Have people in his inner circle drive up the average volume so he can buyback more.
Question for everyone mad. Why would Henry ever post financials before starting buyback &/or Insiders(himself) buy up shares for themselves?
I’m not gonna lie I’m pretty surprised it’s under 14 billion... Works for me sounds like we still have a chance here. People are still buying...
Interesting mini is MIA... wondering if those were all his shares he just sold...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152525139
You said this a year ago too...
Thanks for that Captain obvious
PHIG is associated with Phi Group if you look on Yahoo Finance... There was some volume today at 8. Is this in case PHIL gets delisted???
Did you sell your 100 million today?
Are you still optimistic? Didn’t see you on the CC...
Unfortunately I think you are 100% correct. Thanks for all you information
Damnit! vinafilms is starting to look more fake to me... I tried emailing and they said it wasn’t even a real address... Please someone tell me I’m wrong!!!
Why would a three week quarantine hold up an audit? Someone who was quarantined would have nothing to do but work on the audit it should get done faster. Very typical tweet from Henry leaving it very vague when anything would be accomplished.